Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Incyte Corp (INCY)  
$62.11 0.58 (0.93%) as of 4:30 Fri 6/14


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 219,000,000
Market Cap: 13.60(B)
Last Volume: 4,892,041 Avg Vol: 1,656,287
52 Week Range: $51.18 - $66.59
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:

    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  144
Guru Rank Value     : 7.1
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. JAKAFI (ruxolitinib) is Co.'s initial product approved by the U.S. Food and Drug Administration for the treatment of adults with intermediate or high-risk myelofibrosis, for the treatment of adults with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea, for the treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older and for the treatment of chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 1,093 9,115 40,352 139,368
Total Sell Value $64,389 $589,575 $2,579,669 $10,851,936
Total People Sold 1 3 4 7
Total Sell Transactions 1 3 7 16
End Date 2024-03-17 2023-12-15 2023-06-16 2022-06-16

   
Records found: 1564
  Page 4 of 63  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Brawley Otis W Director   –       •      –    2023-06-14 4 A $0.00 $0 D/D 2,505 5,904     -
   Fouse Jacqualyn A Director   –       •      –    2023-06-14 4 A $0.00 $0 D/D 2,505 13,978     -
   High Katherine A Director   –       •      –    2023-06-14 4 A $0.00 $0 D/D 2,505 7,993     -
   Clancy Paul J Director   –       •      –    2023-06-14 4 A $0.00 $0 D/D 2,505 14,211     -
   Baker Felix Director   –       •       •   2023-06-14 4 A $0.00 $0 I/I 5,010 33,445,860     -
   Cagnoni Pablo J President, R&D   •       –      –    2023-06-05 4/A A $0.00 $0 D/D 192,400 192,400     -
   Cagnoni Pablo J President, R&D   •       –      –    2023-06-05 4 A $0.00 $0 D/D 179,613 179,613     -
   Dhanak Dashyant EVP & Chief Scientific Officer   •       –      –    2023-02-16 4 OE $65.42 $241,596 D/D 3,693 56,956     -
   Stamoulis Christiana EVP & Chief Financial Officer   •       –      –    2023-02-13 4 D $80.08 $94,414 D/D (1,179) 76,460     -
   Pasquale Maria E EVP & General Counsel   •       –      –    2023-01-31 4 AS $84.06 $67,416 D/D (802) 68,524 -28%     
   Pasquale Maria E EVP & General Counsel   •       –      –    2023-01-31 4 OE $74.78 $59,974 D/D 802 69,326     -
   Pasquale Maria E EVP & General Counsel   •       –      –    2023-01-30 4 AS $84.69 $5,086,569 D/D (60,024) 68,524 -26%     
   Pasquale Maria E EVP & General Counsel   •       –      –    2023-01-30 4 OE $65.36 $4,405,224 D/D 60,024 73,366     -
   Iyengar Vijay K EVP, GMAPPS   •       –      –    2023-01-26 4 AS $85.00 $595,000 D/D (7,000) 42,835 -28%     
   Iyengar Vijay K EVP, GMAPPS   •       –      –    2023-01-26 4 OE $68.62 $480,340 D/D 7,000 49,835     -
   Dhanak Dashyant EVP & Chief Scientific Officer   •       –      –    2023-01-26 4 AS $85.00 $205,615 D/D (2,419) 53,263 -28%     
   Dickinson Jonathan Elliott EVP, General Manager, Europe   •       –      –    2023-01-20 4 A $0.00 $0 D/D 6,159 36,338     -
   Stamoulis Christiana EVP & Chief Financial Officer   •       –      –    2023-01-20 4 A $0.00 $0 D/D 4,980 77,639     -
   Flannelly Barry P EVP & General Manager US   •       –      –    2023-01-20 4 A $0.00 $0 D/D 4,980 77,654     -
   Pasquale Maria E EVP & General Counsel   •       –      –    2023-01-20 4 A $0.00 $0 D/D 4,980 68,524     -
   Hoppenot Herve Chairman / CEOPresident   •       •      –    2023-01-20 4 A $0.00 $0 D/D 29,196 435,139     -
   Tray Thomas Principal Accounting Officer   •       –      –    2023-01-20 4 A $0.00 $0 D/D 2,833 19,439     -
   Stein Steven H EVP & Chief Medical Officer   •       –      –    2023-01-20 4 A $0.00 $0 D/D 4,980 114,001     -
   Swain Paula J EVP, Human Resources   •       –      –    2023-01-20 4 A $0.00 $0 D/D 4,980 84,673     -
   Dhanak Dashyant EVP & Chief Scientific Officer   •       –      –    2023-01-20 4 A $0.00 $0 D/D 4,980 55,682     -

  1564 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 4 of 63
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed